What is the recommended dose of urokinase for local intra‑access infusion in a dialysis fistula?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 22, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Urokinase Dosing for Dialysis Fistula Thrombosis

For local intra-access infusion in a thrombosed dialysis fistula, urokinase should be administered at 300,000 IU per session, which can be repeated up to three times if needed for successful thrombolysis 1.

Evidence-Based Dosing Recommendations

Primary Dosing Protocol

The most robust evidence for arteriovenous fistula (AVF) thrombolysis comes from a comparative study demonstrating that 300,000 IU of urokinase administered via local venous infusion achieved an 85.7% cumulative success rate after up to three treatment sessions 1. This approach proved superior to peripheral venous administration (68.4% success rate) and resulted in significantly fewer bleeding complications.

Alternative Dosing from Clinical Experience

Other research protocols have used variable dosing:

  • 243,000 IU ± 100,000 IU for local thrombolytic infusion in conjunction with angiography, achieving immediate patency in 86% of cases 2
  • Bolus administration techniques without specific dosing mentioned, though these focused on Brescia-Cimino fistulas specifically 3

Context: Catheter vs. Fistula Dosing

Important distinction: The KDOQI guidelines primarily address central venous catheter (CVC) dysfunction, where they reference 5,000 IU/mL of urokinase with a 40-minute dwell time 4. However, this is fundamentally different from treating a thrombosed fistula, which requires substantially higher doses for effective thrombolysis.

Administration Technique

  • Route: Local venous infusion directly into the thrombosed access is superior to peripheral venous administration
  • Frequency: Can repeat up to 3 sessions if initial thrombolysis is incomplete
  • Timing: Earlier intervention (within 72 hours) yields significantly better results than subacute thrombosis (>72 hours), with success rates of 79.5% vs. 42.9% respectively 5

Clinical Factors Affecting Success

Protective factors for thrombolysis success include:

  • Higher systolic blood pressure (OR=1.10)
  • Higher diastolic blood pressure (OR=1.08)

Risk factors include:

  • Older thrombus age (OR=0.91) 1

Safety Profile

Local infusion at 300,000 IU demonstrates favorable safety compared to peripheral administration:

  • Less ecchymosis: 4.1% vs. 14.0%
  • Less epistaxis: 2.0% vs. 10.5%
  • Less gingival bleeding: 4.1% vs. 19.3% 1

Common Pitfall

Do not confuse catheter locking doses with fistula thrombolysis doses. Catheter maintenance uses 5,000-25,000 IU for prophylaxis 4, 6, while acute fistula thrombosis requires 300,000 IU for therapeutic effect. Using catheter-level dosing for fistula thrombosis will result in treatment failure.

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.